Regenerating ideas
Working as the Chief Executive Officer of China-based 3D bioprinting startup Revotek, Yin Xie is spearheading the world first clinical trial for 3D bioprinted stem cell vascular grafts for patients with Peripheral Artery Diseases (PADs) in 2022. After receiving the National Health Commission of China approval, Yin Xie and her team are all set to provide regenerative therapies for a range of chronic diseases. She has 15 years of public agency experience and 8 years of executive experience, with 4 years of experience in international business project operation and brand management.
“I BELIEVE THAT IN THE FUTURE, A LARGE NUMBER OF CUTTING-EDGE SCIENTIFIC AND TECHNOLOGICAL ACHIEVEMENTS WILL CONTINUE TO BE PRODUCED.”